My watch list  

Roche Announces Thomas Schinecker as New President of 454 Life Sciences


454 Life Sciences, a center of excellence of Roche’s business unit Applied Science,  announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates, Head of Applied Science.

Dr. Schinecker is currently the Diagnostics General Manager of Sweden, located in Bromma, a suburb of Stockholm.  Dr. Schinecker’s extensive background and experience of over eight years at Roche will be instrumental in guiding 454 Life Sciences into the next generation of pyrosequencing. Dr. Schinecker holds a PhD in oncology, studying at the New York University. He then excelled in several leadership positions in the Sales & Marketing organization of Roche Diagnostics Austria, starting his career at Roche in the Perspectives Program in 2003. With his success in several key management positions within Roche Diagnostics, Dr. Schinecker brings the required organizational and operating skills to 454 Life Sciences’ highly innovative and accurate long sequence read technology. 454 Sequencing Systems are used productively by large numbers of life science researchers in cancer, infectious disease, immunogenetics, drug discovery, agriculture and other disciplines, resulting in more than 1,000 peer-reviewed publications.

Facts, background information, dossiers
  • 454 Life Sciences
  • Roche
More about 454 Life Sciences
More about Roche
  • News

    Roche to restructure its manufacturing network for small molecules

    Roche announced plans to restructure its manufacturing network for small molecules to address current underutilisation as a result of its evolving portfolio. A new generation of specialised medicines based on small molecules requires novel manufacturing technologies and will be produced in ... more

    Roche to acquire Kapa Biosystems

    Roche announced that it has signed a definitive agreement to acquire Kapa Biosystems, Inc. (Kapa) a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to opti ... more

    Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease

    Evotec AG was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease ("AD"). In this study, Sembragiline failed to demonstrate benefit on the primary endpoint (Alzheimer' ... more

  • Companies

    Roche Deutschland Holding GmbH


    Roche Austria GmbH

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more

More about Roche Diagnostics
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE